MQSA Mammography Patient Letter Disclosure Policy: Required Language, Breast Density Notice, and Compliance Guide

MQSA Patient Lay Summary Requirements

Purpose and scope

The Mammography Quality Standards Act (MQSA) requires that every patient receive a clear, plain‑language patient lay summary of mammography results in addition to the medical report sent to the referring provider. The summary must be understandable to non‑clinicians, actionable, and consistent with patient communication standards.

What the patient lay summary must include

• Patient identifiers and the exam date(s).
• Facility name, address, and a direct phone number for questions or scheduling.
• A concise explanation of findings aligned with the final assessment and next steps (for example, routine screening interval or additional imaging).
• A statement that a full medical report was or will be sent to the ordering or designated provider.
• The FDA‑required breast density notification using the standardized language mandated by the final rule.
• Clear instructions on what the patient should do next and how to obtain images or reports.
• Language access and accessibility information, when applicable (for example, availability of translations or large‑print versions).

Format and readability expectations

• Target a 6th–8th grade reading level; use short sentences and familiar terms.
• Highlight key actions (“What this means” and “What you should do next”).
• Keep the letter concise (ideally one page) and free of jargon; define any essential clinical terms.
• Offer translated versions based on patient preference and ensure equivalent accuracy across languages.

Delivery and responsibility

• Deliver the patient lay summary by secure portal, mail, or in person; verify addresses and track returns or portal read receipts when available.
• For self‑referred patients or those without a listed provider, the facility remains responsible for direct patient notification.

Standardized Breast Density Language

Use FDA‑specified wording verbatim

The final rule under the Mammography Quality Standards Act mandates standardized breast density language. Each patient letter must include one—and only one—of the FDA‑specified statements indicating that the patient’s breast tissue is “dense” or “not dense.” Do not paraphrase or edit this required language; embed it verbatim in the patient lay summary.

How to present the breast density notification

• Place a clear subheading such as “Breast Density Notification” within the letter to improve visibility.
• State the patient’s density status and include the FDA text that explains what density means, its implications for cancer detection, and the recommendation to discuss with a healthcare provider.
• Ensure translations mirror the required meaning precisely; verify equivalence through back‑translation or certified translation workflows.

Clinical context that supports understanding

• Explain briefly that dense breast tissue is common and may make cancers harder to see on a mammogram.
• Note that supplemental screening may be considered based on personal risk, history, and clinician guidance; avoid blanket recommendations in the letter.

Timely Disclosure Practices

Core timelines

• Provide the patient lay summary as soon as feasible and no later than 30 calendar days after the examination.
• For results that are suspicious or highly suggestive of malignancy, make direct communication to the patient (and provider) as quickly as possible using telephone or other immediate methods, and document all reasonable attempts.
• Transmit the medical report to the referring provider promptly; if no provider is identified, notify the patient directly and assist with next‑step coordination.

Sample operational workflow

• Day 0–1: Interpretation finalized; preliminary communication initiated for urgent findings.
• Day 0–2: Medical report delivered to the referring provider or designated clinician.
• Day 0–5: Patient lay summary generated with the required breast density notification and sent via the preferred channel.
• By Day 30: Confirm delivery or document reasonable attempts; escalate unresolved or returned communications.

Handling unreachable patients

• Use multiple modalities (phone, secure portal, mail) and confirm contact information at check‑in.
• Document each outreach attempt, outcome, and escalation path; retain returned mail for inspection records.

Compliance with FDA Final Rule

Implementation checklist for FDA final rule compliance

• Update letter templates to insert the exact FDA breast density wording and automate selection of “dense” vs. “not dense.”
• Embed the density section within the patient lay summary so it appears on every final letter.
• Validate readability, translation accuracy, and accessibility (for example, large‑print or screen‑reader‑friendly formats).
• Train technologists, radiologists, and front‑line staff on the revised workflow and escalation steps.
• Map your process to mammography facility requirements, including audit logs, template version control, and proof of timely disclosure.
• For multi‑state operations, harmonize letters across locations while retaining the federal wording; add any state‑specific elements without altering the FDA text.

Inspection readiness

• Maintain a policy that describes your MQSA Mammography Patient Letter Disclosure Policy end‑to‑end.
• Keep exemplars of each letter version (“dense” and “not dense”), including translations and revision histories.
• Retain mailing logs, portal delivery reports, and documentation of returned mail and re‑send actions.
• Track turnaround‑time metrics to demonstrate adherence to patient communication standards.

Communication Best Practices

Write for clarity and action

• Lead with the result, then the next step the patient should take; avoid hedging and jargon.
• Use headings, bullets, and white space so key messages are scannable.
• Define essential terms (for example, “additional imaging” or “follow‑up appointment”) in one short sentence.

Empathy and tone

• Acknowledge that waiting for results can be stressful; offer a direct line for questions.
• Use supportive, non‑alarmist language while being transparent about any recommended follow‑up.

Equity and accessibility

• Provide translated summaries upon request and interpreter support for phone follow‑ups.
• Offer accessible formats, including large‑print and screen‑reader‑compatible letters.
• Confirm communication preferences at registration (portal, mail, phone) and honor them whenever possible.

Handling Patient Queries

Set up a clear triage pathway

• Scheduling and logistics to front‑desk or access team.
• Clinical result questions to a nurse navigator or radiologist, as defined by protocol.
• Risk and supplemental screening discussions routed to qualified clinicians for individualized guidance.

Answering common questions

• Normal result: “Your mammogram showed no findings of concern. Please continue routine screening as recommended by your provider.”
• Recall needed: “We need additional views or ultrasound to clarify an area; this is common and does not mean cancer. Let’s schedule the follow‑up.”
• Dense breast tissue disclosure: “Many people have dense tissue. It can make cancers harder to see and may slightly increase risk. Talk with your provider about whether any additional screening fits your personal risk.”

Privacy and documentation

• Verify patient identity before discussing results by phone or in person.
• Document questions asked, guidance provided, and any appointments scheduled.
• Escalate unresolved clinical concerns promptly and record the handoff.

Documentation and Record-Keeping

What to capture

• Copies of every patient lay summary and the date/time and method of delivery.
• Logs of phone calls, portal messages, mailed letters, and any returns or failed deliveries.
• Evidence that the standardized breast density notification appeared with correct wording.
• Training records, policies, and versioned templates showing change history.

Retention and retrieval

• Maintain images and reports per MQSA requirements—at least five years, or ten years if no subsequent mammograms are performed at your facility—while adhering to any longer state requirements.
• Retain communication logs and letter copies for inspection and medico‑legal needs; make them readily retrievable.
• Provide images and results to the patient or designated provider upon request within a defined turnaround time.

Monitoring and quality improvement

• Track key performance indicators: percentage of letters sent within 30 days, median days to delivery, direct‑contact time for urgent results, and return‑mail rates.
• Audit a sample of letters monthly for readability, correct density wording, and accurate next‑step instructions.
• Use findings to update staff training and refine templates; document corrective actions.

Conclusion

Consistent use of the required breast density language, timely patient lay summaries, and rigorous documentation are central to FDA final rule compliance. By standardizing workflows, training staff, and auditing results, your facility can meet mammography facility requirements and deliver clear, compassionate communication that patients trust.

FAQs.

What is the MQSA requirement for mammography patient letters?

Under MQSA, every patient must receive a plain‑language patient lay summary of results in addition to the medical report sent to the provider. The summary must include the FDA‑mandated breast density notification, facility contact information, a concise description of findings, and clear next steps.

How must breast density be disclosed in patient summaries?

Each letter must contain the FDA‑specified standardized wording that states whether the patient’s tissue is “dense” or “not dense,” along with explanatory text. The required language must appear verbatim in the patient lay summary and should not be paraphrased or omitted.

When must mammography results be provided to patients?

Provide results to patients as soon as feasible and no later than 30 calendar days after the exam for routine findings. For results that are suspicious or highly suggestive of malignancy, make direct patient communication as quickly as possible and document all reasonable attempts.

What are the consequences of non-compliance with MQSA disclosure policies?

Facilities may face inspection citations, corrective action plans, civil penalties, or suspension/revocation of the mammography certificate. Non‑compliance also increases medico‑legal risk, undermines patient trust, and can jeopardize accreditation and payer relationships.